

## References

1. Venis S. Mixed benefits of hormone replacement therapy. *Lancet* 2002; 359(9305): 501.
2. Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. *Alternative Medicine Review* 2006; 11(3): 208–223.
3. Thunell L, Stadberg E, Milsom I et al. A longitudinal population study of climacteric symptoms and their treatment in a random sample of Swedish women. *Climacteric* 2004; 7(4): 357–365.
4. Cohen O, Vinker S, Yaphe J et al. Hormone replacement therapy and WONCA/COOP functional status: A cross-sectional population-based study of women in Israel. *Climacteric* 2005; 8(2): 171–176.
5. McGinley AM. Health beliefs and women's use of hormone replacement therapy. *Holist Nurs Pract* 2004; 18(1): 18–25.
6. Francisco L. Is bio-identical hormone therapy fact or fairy tale? *Nurse Pract* 2003; 28(7 Pt 1): 39–44.
7. Ness J, Aronow WS, Newkirk E et al. Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. *J Gerontol A Biol Sci Med Sci* 2005; 60(4): 460–462.
8. Penckofer S, Schwertz D. Hormone replacement therapy: Primary and secondary prevention. *J Cardiovasc Nurs* 2001; 15(3): 1–25.
9. Cutter B, Vail J. Natural or bioidentical hormone replacement: What makes the difference? An interview with Christopher B. Cutter, MD. *IJPC* 2003; 7(1): 24–26.
10. Vigasaa KA, Downhour NP, Chui MA et al. Efficacy and tolerability of compounded bioidentical hormone replacement therapy. *IJPC* 2004; 8(4): 313–319.
11. Santoro F. Satisfaction of patients using bioidentical hormones for hormone replacement therapy. *IJPC* 2002; 6(5): 377–378.
12. Watt PJ, Hughes RB, Rettew LB et al. A holistic programmatic approach to natural hormone replacement. *Fam Community Health* 2003; 26(1): 53–63.
13. Patients and Professionals for Customized Care. *Oprah Winfrey continues bioidentical hormone replacement therapy*. Available at: <http://us.mc844.mail.yahoo.com/mg/show/message?fib=Inbox&sort>. Accessed January 30, 2009.
14. Allina A, Fugh-Berman A. Evidence-based Perspectives on Hot Women's Health Issues: Natural hormones—Are they a safe alternative? [Gillian Sanson Website.] 2007. Available at <https://gilliansanson.wordpress.com/2007/03/28/natural-hormones-are-they-a-safe-alternative>. Accessed September 19, 2016.
15. Holt-Waldo NY, Stephenson K. The lived experience of perimenopausal and menopausal women undergoing treatment with bioidentical human hormones. *IJPC* 2007; 11(4): 292–296.
16. Goodrum J. Estriol: Women's choice vs. a manufacturer's greed. *IJPC* 2008; 12(4): 286–292.
17. U.S. Department of Health & Human Services. U.S. Food & Drug Administration. *News & Events: FDA Takes Action Against Compounded Menopause Hormone Therapy Drugs*. [FDA Website.] January 9, 2008. Available at: [www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/usm116832.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/usm116832.htm). Accessed November 25, 2008.
18. Lenz ER, Pugh LC, Milligan RA et al. The middle-range theory of unpleasant symptoms: An update. *ANS Adv Nurs Sci* 1997; 19(3): 14–27.
19. Gift A. Unpleasant symptoms. In: Bredow TS, Peterson SJ, eds. *Middle Range Theories: Application to Nursing Research*. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004.
20. Buick DL, Crook D, Horne R. Women's perceptions of hormone replacement therapy: Risks and benefits (1980–2002). A literature review. *Climacteric* 2005; 8(1): 24–35.
21. The North American Menopause Society. *Menopause Practice Textbook. Menopause Practice: A Clinician's Guide*. 5th ed. [NAMS Website.] Available at: [www.menopause.org/publications/professional-publications/-i-menopause.practice-i-menopause/-i-menopause-practice-i-textbook](http://www.menopause.org/publications/professional-publications/-i-menopause.practice-i-menopause/-i-menopause-practice-i-textbook). Accessed January 20, 2007.
22. Wright J, Morgenthaler J. Don't let your doctor give you horse urine! There Are Better Treatments for Menopause. [Eternity Medicine Website.] October 30, 2002. Available at: [www.eternity-medicine.com/English/04\\_eternity-medicine\\_products/Progesterone/progesterone\\_article.pdf](http://www.eternity-medicine.com/English/04_eternity-medicine_products/Progesterone/progesterone_article.pdf). Accessed September 19, 2016.
23. Reed-Kane D. Natural hormone replacement therapy: What it is and what consumers really want. *IJPC* 2001; 5(5): 332–333.
24. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. *Breast Cancer Res Treat* 2008; 107(2): 103–111.
25. Leonetti HB, Landes J, Steinberg D et al. Transdermal progesterone cream as an alternative progestin in hormone therapy. *Altern Ther Health Med* 2005; 11(6): 36–38.
26. Montplaisir J, Lorrain J, Denesle R et al. Sleep in menopause: Differential effects of two forms of hormone replacement therapy. *Menopause* 2001; 8(1): 10–18.
27. Lookinland S, Beckstrand RL. HRT: Decide based on the evidence. *Nurse Pract* 2003; 28(9): 46–54.
28. Bakken K, Eggen AE, Lund E. (2004). Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45–64 years. The Norwegian Women and Cancer (NOWAC) Study 1997. *Acta Obstetrica et Gynecologica Scandinavica* 2004; 83: 850–856.
29. Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: Randomised controlled trial. *BMJ* 2008; 337: a1190.
30. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: What shall we do now? *Lancet* 2005; 366(9483): 409–421.
31. Rudolph I, Palombo-Kinne E, Kirsch B et al. Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression. *Climacteric* 2004; 7(3): 301–311.